Chasing US Lead, Japan s GeneCare Takes Aim at Cancer With RNA Interference-Based Therapeutics | GenomeWeb

As the world’s second-largest pharmaceutical market, it should come as no surprise that Japan is home to a wide variety of drug developers. And just like in the US, the world’s biggest drugs market, the majority of Japanese pharmas are focused on small molecules.

However, as the potential of RNA interference grows, so, too, does the number of Japanese companies exploring the gene-silencing technology as a therapeutic modality. One of these is GeneCare Research Institute, which claims to be Japan’s only RNAi-based drug developer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.